Repression of SLC22A3 by the AR-V7/YAP1/TAZ Axis in Enzalutamide-Resistant Castration-Resistant Prostate Cancer

Researchers observed low SLC22A3 expression and high levels of TAZ or YAP1 in metastatic castration-resistant prostate cancer patient tissues harboring androgen receptor splice variant 7.